Guided Therapeutics (GTHP) Long-Term Deferred Tax (2013 - 2025)

Guided Therapeutics (GTHP) posted Long-Term Deferred Tax of $15.6 million for Q4 2025, down 4.82% sequentially from $16.4 million in Q4 2023.

Guided Therapeutics (GTHP) Long-Term Deferred Tax (2013 - 2025) Analysis & Trends

Guided Therapeutics has reported Long-Term Deferred Tax for 6 years, with the latest figure at $15.6 million in Q4 2025.

Quarterly Long-Term Deferred Tax changed N/A year-over-year to $15.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $15.6 million (changed N/A YoY) and the FY2025 annual result came in at $15.6 million, changed N/A from the prior year.
Long-Term Deferred Tax fell to $15.6 million in Q4 2025 per GTHP's latest filing, from $16.4 million in the prior quarter.
Over five years, Long-Term Deferred Tax peaked at $17.1 million in Q4 2022 and troughed at $15.6 million in Q4 2025.
A 3-year average of $16.4 million and a median of $16.4 million in 2023 frame the typical range for Long-Term Deferred Tax.
The widest YoY moves for Long-Term Deferred Tax: up 3.91% in 2023, down 3.91% in 2023.
Over 3 years, Long-Term Deferred Tax stood at $17.1 million in 2022, then decreased by 3.91% to $16.4 million in 2023, then dropped by 4.82% to $15.6 million in 2025.
According to Business Quant data, Long-Term Deferred Tax over the past three periods registered $15.6 million, $16.4 million, and $17.1 million for Q4 2025, Q4 2023, and Q4 2022 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Abbott Laboratories	199.44 Bn	193.84 Bn	7.27 Bn
2	Stryker	127.32 Bn	123.85 Bn	4.50 Bn
3	Medtronic	118.87 Bn	109.65 Bn	6.41 Bn
4	Boston Scientific	73.47 Bn	72.93 Bn	3.85 Bn
5	Edwards Lifesciences	51.90 Bn	47.65 Bn	1.35 Bn
6	Dexcom	34.30 Bn	32.36 Bn	830.00 Mn
7	GE HealthCare Technologies	33.74 Bn	31.63 Bn	2.18 Bn
8	Koninklijke Philips	26.35 Bn	23.03 Bn	4.55 Bn
9	Steris	23.05 Bn	22.56 Bn	684.20 Mn
10	Guided Therapeutics	26.06 Mn	26.05 Mn	-

Download Data